Dear user, the application need JavaScript support. Please enable JavaScript in your browser.

You are browsing as a GUEST
Title of the item:

The EORTC breast cancer group: a major achievements of 50 years of research and future directions.

Title :
The EORTC breast cancer group: a major achievements of 50 years of research and future directions.
Authors :
Cufer, Tanja
Cardoso, Fatima
Werutsky, Gustavo
Bonnefoi, Herve
Brain, Etienne
Cataliotti, Luigi
Dal Lago, Lissandra
Delaloge, Suzette
Jassem, Jacek
van Tienhoven, Geertjan
Van't Veer, Laura
Westenberg, Helen
Marreaud, Sandrine
Bogaerts, Jan
Rutgers, Emiel
Cameron, David
Show more
Source :
EJC Supplements; Mar2012, Vol. 10 Issue 1, p27-33, 7p
Academic Journal
The EORTC Breast Cancer Group (BCG), created in 1962, is a multidisciplinary group involving surgeons, medical oncologists, radiation oncologists, pathologists, basic scientists, and clinical research fellows. Currently, more than 80 member's institutions across Europe are participating in the group studies. The main goal of the BCG is to conduct high-quality international clinical trials covering all areas of breast cancer care: from loco-regional to systemic disease control, and from in situ carcinoma to metastatic disease. Over 50 years, the BCG has performed dozens of clinical studies including several thousands of patients. Many practice-changing trials and major achievements were conducted optimizing local control, improving systemic therapy in early and metastatic breast cancer, pioneering work in clinical-translational trials and collaboration within intergroup trials. The strategic plan of the BCG for future research includes three distinct albeit overlapping areas: loco-regional therapy, (neo-)adjuvant systemic therapy, trials in the metastatic setting, and niche population studies. For each of these areas the group has considered the prevailing EORTC strategy of focusing on practice-changing studies and translational research, with an emphasis on niche trials. During five decades, the BCG has successfully performed a series of practice-changing trials enrolling several thousands of patients. These studies have contributed to the clinical knowledge on the treatment of breast cancer and have influenced clinical practice and breast cancer patients' outcome worldwide. [ABSTRACT FROM AUTHOR]
Copyright of EJC Supplements is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

We use cookies to help identify your computer so we can tailor your user experience, track shopping basket contents and remember where you are in the order process.